MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $7.27 Million Stake in Insmed Incorporated (NASDAQ:INSM)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 10.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 105,313 shares of the biopharmaceutical company's stock after buying an additional 10,352 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.06% of Insmed worth $7,270,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. National Bank of Canada FI increased its position in Insmed by 9.7% in the fourth quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company's stock worth $115,000 after buying an additional 147 shares during the period. Abel Hall LLC increased its holdings in shares of Insmed by 4.7% during the fourth quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company's stock valued at $230,000 after purchasing an additional 151 shares during the period. Steward Partners Investment Advisory LLC increased its holdings in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 163 shares during the period. M&T Bank Corp increased its holdings in shares of Insmed by 5.6% during the fourth quarter. M&T Bank Corp now owns 3,146 shares of the biopharmaceutical company's stock valued at $217,000 after purchasing an additional 166 shares during the period. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Insmed by 5.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company's stock valued at $244,000 after purchasing an additional 183 shares during the period.

Analysts Set New Price Targets

INSM has been the topic of a number of research analyst reports. Wells Fargo & Company raised their price target on Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a report on Wednesday, February 19th. Guggenheim reissued a "buy" rating and set a $101.00 price target on shares of Insmed in a report on Tuesday, February 25th. Stifel Nicolaus lowered their price target on Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a report on Friday, February 21st. Truist Financial raised their price target on Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a report on Friday, February 21st. Finally, JPMorgan Chase & Co. raised their price target on Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $94.63.

Insmed Price Performance

INSM stock traded up $1.37 during trading hours on Friday, hitting $67.53. 1,545,805 shares of the stock traded hands, compared to its average volume of 2,334,404. The stock has a 50-day simple moving average of $70.69 and a 200 day simple moving average of $73.05. Insmed Incorporated has a one year low of $21.92 and a one year high of $84.91. The company has a market cap of $12.30 billion, a P/E ratio of -12.08 and a beta of 0.84. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). The company had revenue of $92.82 million during the quarter, compared to analysts' expectations of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company's revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.06) EPS. Equities analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Michael Alexander Smith sold 409 shares of Insmed stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $65.61, for a total transaction of $26,834.49. Following the completion of the sale, the insider now directly owns 91,794 shares in the company, valued at $6,022,604.34. The trade was a 0.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO William Lewis sold 18,750 shares of Insmed stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $77.79, for a total value of $1,458,562.50. Following the sale, the chief executive officer now owns 334,186 shares of the company's stock, valued at approximately $25,996,328.94. This represents a 5.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 153,098 shares of company stock valued at $10,724,192. 3.00% of the stock is owned by corporate insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.